
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt about any of the contents of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your Shares in **Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**, you should at once hand this circular together with the proxy form to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9989)

**REAPPOINTMENT OF ACCOUNTING FIRMS
CREDIT LINE APPLICATION TO CHINA GUANGFA BANK AND
INDUSTRIAL BANK AND PROVISION OF GUARANTEES
CREDIT APPLICATION TO CHINA DEVELOPMENT BANK AND
PROVISION OF GUARANTEES
CREDIT LINE ADJUSTMENT OF BANK OF CHINA AND
PROVISION OF GUARANTEES
AND
NOTICE OF THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING**

A letter from the Board is set out on pages 3 to 11 of this circular. A notice of the extraordinary general meeting (the "EGM") to be held at 2:30 p.m. on Tuesday, December 15, 2020 at Ballroom, 2/F, L'Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC, is being dispatched to the Shareholders together with this circular.

Shareholders who intend to appoint a proxy to attend the EGM shall complete and return the proxy form in accordance with the instructions printed thereon. The proxy form must be signed by you or your attorney duly authorised in writing or, in case of a legal person, must either be executed under its seal or under the hand of its director or other attorney duly authorised to sign the same. If the proxy form is signed by an attorney of the appointor, the power of attorney authorising that attorney to sign, or other document of authorisation, must be notarized.

In the case of joint holders of the Shares, only the holder whose name stands first in the register of members of the Company shall alone be entitled to vote at the EGM, either in person or by proxy in respect of such Shares.

For H Share Shareholders, please return the proxy form together with any documents of authority to the Company's H Share registrar, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong as soon as possible, and in any event not later than 24 hours before the time appointed for holding the EGM. For A Share Shareholders, please return the proxy form together with any documents of authority to the headquarters of the Company in the PRC at No. 21 Langshan Road, Nanshan District, Shenzhen, the PRC as soon as possible, and in any event not later than 24 hours before the time appointed for holding the EGM. Completion and return of the proxy form will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish.

November 24, 2020

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	3
1. INTRODUCTION	4
2. REAPPOINTMENT OF ACCOUNTING FIRMS	4
3. CREDIT LINE APPLICATION TO CHINA GUANGFA BANK AND INDUSTRIAL BANK AND PROVISION OF GUARANTEES	5
4. CREDIT APPLICATION TO CHINA DEVELOPMENT BANK AND PROVISION OF GUARANTEES	7
5. CREDIT LINE ADJUSTMENT OF BANK OF CHINA AND PROVISION OF GUARANTEES	8
6. THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING	10
7. RECOMMENDATION	11
NOTICE OF THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING	12

Note: If there are any discrepancies between the Chinese version and the English version of this circular, the Chinese version shall prevail.

DEFINITIONS

In this circular, unless the context otherwise requires, the following terms shall have the following meanings:

“A Share(s)”	domestic share(s) issued by the Company, with a nominal value of RMB1.00 each, which are subscribed for or credited as paid in Renminbi and are listed for trading on the Shenzhen Stock Exchange
“A Share Shareholder(s)”	the holder(s) of the A Share(s)
“Articles of Association”	the articles of association of the Company
“Board”	the board of directors of the Company
“Company”	Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (深圳市海普瑞藥業集團股份有限公司), a joint stock company incorporated in the PRC with limited liability, whose A Shares are listed on the Shenzhen Stock Exchange (stock code: 002399) and whose H Shares are listed on the main board of the Hong Kong Stock Exchange (stock code: 9989)
“EGM”	the extraordinary general meeting of the Company to be convened and held at 2:30 p.m. on Tuesday, December 15, 2020
“Group”	the Company and its subsidiaries, and their respective predecessors
“Hepalink (Hong Kong)”	Hepalink (Hong Kong) Limited (海普瑞(香港)有限公司), a company incorporated in Hong Kong on November 23, 2010 and a wholly-owned subsidiary of our Company
“HK dollars”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“H Share(s)”	overseas listed foreign share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for and traded in HK dollars and listed on the Main Board of the Hong Kong Stock Exchange
“H Share Shareholder(s)”	the holder(s) of the H Share(s)

DEFINITIONS

“Latest Practicable Date”	November 17, 2020, being the latest practicable date for the purpose of ascertaining certain information contained in this circular prior to its publication
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China, which, for the purpose of this circular, excludes Hong Kong, the Macau Special Administrative Region and Taiwan
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, comprising the A Share(s) and H Share(s)
“Shareholder(s)”	holder(s) of the Share(s)
“Shenzhen Stock Exchange”	the Shenzhen Stock Exchange (深圳證券交易所)
“Shenzhen Techdow”	Shenzhen Techdow Pharmaceutical Co., Ltd. (深圳市天道醫藥有限公司), a Company incorporated in the PRC with limited liability on June 29, 2004, and a wholly-owned subsidiary of our Company
“Stock Exchange” or “Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited

LETTER FROM THE BOARD



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9989)

Executive Directors:

Mr. Li Li (*Chairman*)
Ms. Li Tan
Mr. Shan Yu (*General Manager*)
Mr. Sun Xuan (*Vice Chairman*)

Registered office in the PRC:

No. 21 Langshan Road
Nanshan District
Shenzhen
PRC

Non-executive Director:

Mr. Bu Haihua

Principal place of business

in Hong Kong:
Room 4724, 47th Floor,
Sun Hung Kai Center
30 Harbour Road, Wan Chai
Hong Kong

Independent non-executive Directors:

Dr. Lu Chuan
Mr. Chen Junfa
Mr. Wang Zhaohui

November 24, 2020

To the Shareholders

Dear Sir or Madam,

**REAPPOINTMENT OF ACCOUNTING FIRMS
CREDIT LINE APPLICATION TO CHINA GUANGFA BANK AND
INDUSTRIAL BANK AND PROVISION OF GUARANTEES
CREDIT APPLICATION TO CHINA DEVELOPMENT BANK AND
PROVISION OF GUARANTEES
CREDIT LINE ADJUSTMENT OF BANK OF CHINA AND
PROVISION OF GUARANTEES
AND
NOTICE OF THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING**

LETTER FROM THE BOARD

1. INTRODUCTION

The purpose of this circular is to give you notice of the EGM and to provide you with the information regarding certain ordinary resolution and special resolutions to be proposed at the EGM relating to (including) the following matters in order to enable you to make informed decision on whether to vote for or against such resolutions at the EGM:

At the EGM, ordinary resolution will be proposed to approve, among others,

- (1) Reappointment of accounting firms.

At the EGM, special resolutions will be proposed to approve, among others,

- (1) the credit line application by the Company's wholly-owned subsidiary to China Guangfa Bank and Industrial Bank and provision of guarantees by the Company;
- (2) the credit application by the Company's wholly-owned subsidiary to China Development Bank and provision of guarantees by the Company; and
- (3) the credit line adjustment of Bank of China and provision of guarantees by the Company.

2. REAPPOINTMENT OF ACCOUNTING FIRMS

Ernst & Young Hua Ming LLP (“**Ernst & Young Hua Ming**”) was the domestic financial and internal control auditor of the Company for the year of 2019, while Ernst & Young (“**Ernst & Young**”) was the overseas financial report auditor of the Company for the year of 2019. During their respective work process, both Ernst & Young Hua Ming and Ernst & Young followed the practice standard of “independent, objective, impartial and prudent”, committing to earnestly performing their duties with due diligence and care, issuing annual audit report that could objectively, impartially, truthfully and comprehensively reflect the financial condition and results of operation of the Company, and properly finishing the relevant financial audit work. In order to maintain the continuity and stability of the Company's audit work, the Company intends to reappoint Ernst & Young Hua Ming and Ernst & Young to act as the domestic financial and internal control auditor for the year of 2020 and the overseas financial report auditor for the year of 2020, respectively, where the term of office shall last until the end of the 2020 annual general meeting. It is hereby proposed at the EGM to authorize the Board and the Board to then authorize the management of the Company to determine audit fees for the year of 2020 based on the actual volume of audit work and the market price level of 2020.

The relevant resolution of the Company for the reappointment of accounting firms has been resolved and approved by the fourth provisional meeting of the fifth session of the Board, and subject to approval through an ordinary resolution by the EGM.

LETTER FROM THE BOARD

3. CREDIT LINE APPLICATION TO CHINA GUANGFA BANK AND INDUSTRIAL BANK AND PROVISION OF GUARANTEES

A. Overview of the guarantee

At the second provisional meeting of the fifth session of the Board held on September 18, 2020, the resolution in relation to the application for credit line by the Company's wholly-owned subsidiary and provision of guarantees by the Company has been considered and approved. In order to meet the business development needs of Shenzhen Techdow, the Company and Shenzhen Techdow, its wholly-owned subsidiary, were approved by the Board to apply to the following banks for a comprehensive credit line, and the Company shall provide guarantees to the relevant banks for the partial credit line mentioned below. The details are as follows:

Unit: RMB'0,000

Applicant	Name of bank	Method of guarantee	Line of credit	Term	Use
Shenzhen Techdow	China Guangfa Bank Co., Ltd., Shenzhen Branch	Joint liability guarantee provided by the Company	25,000	12 months	Working capital loans, issuance of electronic bank acceptance bills, domestic letters of credit, outward bills, inward bills, non-financing guarantees, etc.
	Industrial Bank Co., Ltd., Shenzhen Branch	Joint liability guarantee provided by the Company	40,000	12 months	Short-term working capital loans, bank acceptance bills, inward and outward bills, financing guarantees, letters of credit, agency fund transactions, bill poll business, etc.

The Board proposed to the EGM to authorize the chairman to handle relevant procedures relating to the bank credit business and guarantee within the abovementioned scope (including but not limited to specific negotiations with the banks, signing agreements and handling loan procedures, etc.).

LETTER FROM THE BOARD

B. Basic information on the guaranteed party

Company Name:	Shenzhen Techdow Pharmaceutical Co., Ltd.
Unified Social Credit Code:	91440300763486555H
Date of Establishment:	June 29, 2004
Registered Address:	No. 1, Rongtian South, Kengzi Street, Pingshan New District, Shenzhen
Legal Representative:	Li Li
Registered Capital:	RMB150 million
Principal Business:	Research and development, manufacture and sales of enoxaparin sodium active pharmaceutical ingredients and finished dose enoxaparin sodium pharmaceutical products
Relationship with the Company:	Wholly-owned subsidiary
Whether it is a dishonest person subject to enforcement:	No

C. Main content of the guarantee and credit agreement

As at the Latest Practicable Date, no guarantee and credit agreement has been entered into by the Company and Shenzhen Techdow in respect of the above guarantees. The total amount of abovementioned planned credits and guarantees is the line of credit to be applied by Shenzhen Techdow and guarantees to be provided by the Company for this time. The specific amount of credits and guarantees is subject to the actual agreement signed by the Company, Shenzhen Techdow and the banks.

The resolution in relation to the application for credit line by the Company's wholly-owned subsidiary and provision of guarantees by the Company was considered and approved at the second provisional meeting of the fifth session of the Board and is subject to the approval by way of passing a special resolution at the EGM.

LETTER FROM THE BOARD

4. CREDIT APPLICATION TO CHINA DEVELOPMENT BANK AND PROVISION OF GUARANTEES

A. Overview of the guarantee

At the fourth provisional meeting of the fifth session of the Board held on October 29, 2020, the resolution in relation to the application for credit by the Company's wholly-owned subsidiary to China Development Bank and provision of guarantees by the Company was considered and approved. Shenzhen Techdow intends to apply to the Shenzhen Branch of China Development Bank for a comprehensive credit line of not more than US\$30 million or equivalent in Euros with joint liability guarantees with a credit term of 24 months provided by the Company, for the purchase of production materials, payment of staff salaries, payment of upstream and downstream loans, payment of social security, daily operating expenses, etc.

The Board proposed to the EGM to authorize the chairman to handle relevant procedures relating to the bank credit business and guarantee within the abovementioned scope (including but not limited to specific negotiations with the banks, signing relevant agreements and handling loan procedures, etc.).

B. Basic information on the guaranteed party

Company Name:	Shenzhen Techdow Pharmaceutical Co., Ltd.
Unified Social Credit Code:	91440300763486555H
Date of Establishment:	June 29, 2004
Registered Address:	No. 1, Rongtian South, Kengzi Street, Pingshan New District, Shenzhen
Legal Representative:	Li Li
Registered Capital:	RMB150 million
Principal Business:	Research and development, manufacture and sales of enoxaparin sodium active pharmaceutical ingredients and finished dose enoxaparin sodium pharmaceutical products
Relationship with the Company:	Wholly-owned subsidiary
Whether it is a dishonest person subject to enforcement:	No

LETTER FROM THE BOARD

C. Main content of the guarantee and credit agreement

As at the Latest Practicable Date, no guarantee and credit agreement has been entered into by the Company and Shenzhen Techdow in respect of the above guarantees. The total amount of abovementioned planned credits and guarantees is only the guarantees to be provided and the line of credit to be applied by the Company and Shenzhen Techdow for this time. The specific amount of guarantees and credits is subject to the actual contract signed by the Company and Shenzhen Techdow and the banks.

The resolution in relation to the application for credit by the Company's wholly-owned subsidiary to China Development Bank and provision of guarantees by the Company was considered and approved at the fourth provisional meeting of the fifth session of the Board, and is subject to the approval by way of passing a special resolution at the EGM.

5. CREDIT LINE ADJUSTMENT OF BANK OF CHINA AND PROVISION OF GUARANTEES

A. Overview of the guarantee

At the thirty-first meeting of the fourth session of the Board held on March 30, 2020 and the second extraordinary general meeting of 2020 held on April 15, 2020 by the Company, the Proposal on Applying for Credit Line and Providing Guarantees to the Banks for 2020 was considered and approved, in which it has been agreed that the Company to apply to the Bank of China Limited, Shenzhen Zhongxin District Sub-Branch (“**Shenzhen Zhongxin Sub-Branch of Bank of China**”) for a comprehensive credit line not exceeding RMB2,400 million with a credit term of 120 months, and secured by part of the self-owned real estates of the Company; and agreed that Shenzhen Techdow, a wholly-owned subsidiary of the Company, to apply to Shenzhen Zhongxin Sub-Branch of Bank of China for a comprehensive credit line not exceeding RMB100 million with a credit term of 12 months, and secured by joint liability guarantee provided by the Company.

In order to meet the capital requirements of the Company's overall production and operation, it is proposed to adjust the credit line of Shenzhen Zhongxin Sub-Branch of Bank of China among the Company, Shenzhen Techdow and Hepalink (Hong Kong), details are as follows:

Unit: RMB'0,000

Credit objects	Original credit line	Adjusted credit line	Method of guarantee	Credit term	Use
The Company	240,000	200,000	Secured by self-owned real estates	120 months	Medium- to long-term fixed assets loans, medium- to long-term working capital loans, short-term working capital loans, trade financing line, financing guarantees, etc.

LETTER FROM THE BOARD

Credit objects	Original credit line	Adjusted credit line	Method of guarantee	Credit term	Use
Shenzhen Techdow	10,000	40,000	Joint liability guarantee provided by the Company	24 months	Medium- to long-term working capital loans, short- term working capital loans, etc., used for the Company's daily working capital turnover.
The Company, Shenzhen Techdow, Hepalink (Hong Kong)	—	10,000	Joint liability guarantee provided by the Company	12 months	Medium- to long-term working capital loans, short- term working capital loans, etc., used for the Company's daily working capital turnover.
Total	250,000	250,000	—	—	—

The Board proposed to the EGM to authorize the chairman of the Company to deal with relevant matters relating to the bank credit business and guarantee within the abovementioned adjusted scope (including but not limited to specific negotiations with the banks, signing relevant agreements and handling loan procedures, etc.).

B. Basic information on the guaranteed parties

(i) *Shenzhen Techdow*

Company Name:	Shenzhen Techdow Pharmaceutical Co., Ltd.
Unified Social Credit Code:	91440300763486555H
Date of Establishment:	June 29, 2004
Registered Address:	No. 1, Rongtian South, Kengzi Street, Pingshan New District, Shenzhen
Legal Representative:	Li Li
Registered Capital:	RMB150 million
Principal Business:	Research and development, manufacture and sales of enoxaparin sodium active pharmaceutical ingredients and finished dose enoxaparin sodium pharmaceutical products
Relationship with the Company:	Wholly-owned subsidiary
Whether it is a dishonest person subject to enforcement:	No

LETTER FROM THE BOARD

(ii) *Hepalink (Hong Kong)*

Company Name:	Hepalink (Hong Kong) Limited
Registration Certificate Number:	1531390
Date of Establishment:	November 23, 2010
Registered Address:	Room 4724, 47 th Floor, Sun Hung Kai Center, 30 Harbour Road, Wan Chai, Hong Kong
Registered Capital:	HK\$330,221,400
Principal Business:	Trade and import and export
Relationship with the Company:	Wholly-owned subsidiary
Whether it is a dishonest person subject to enforcement:	No

C. Main content of the guarantee and credit agreement

As at the Latest Practicable Date, no guarantee and credit agreement has been entered into by the Company, Shenzhen Techdow and Hepalink (Hong Kong) in respect of the above guarantees. The total amount of abovementioned planned credits and guarantees is only the line of credit to be applied and guarantees to be provided by the Company and its wholly-owned subsidiaries for this time. The specific amount of credits and guarantees is subject to the actual contract signed by the Company and its wholly-owned subsidiaries with the bank.

The Company's proposal in relation to the credit line adjustment of Bank of China and provision of guarantees by the Company was considered and approved at the fourth provisional meeting of the fifth session of the Board and is subject to the approval by way of passing a special resolution at the EGM.

6. THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING

A notice of the EGM to be held at 2:30 p.m. on Tuesday, December 15, 2020 at Ballroom, 2/F, L'Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC, is set out on pages 12 to 13 of this circular.

A proxy form to be used at the EGM is also enclosed herein and published on the website of the Stock Exchange (www.hkexnews.com.hk). H Share Shareholders who intend to appoint a proxy to attend the EGM shall complete, sign and return the proxy form in accordance with the instructions printed thereon.

For H Share Shareholders, the proxy form, and if the proxy form is signed by a person under a power of attorney or other authority on behalf of the appointor, a notarized copy of that power of attorney or other authority, must be delivered to the Company's H Share registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, not less than 24 hours before the time for holding the EGM in order for such documents to be valid.

LETTER FROM THE BOARD

Pursuant to the Articles of Association, for the purpose of holding the EGM, the register of members of H Shares will be closed from Wednesday, December 9, 2020 to Tuesday, December 15, 2020 (both days inclusive), during this period no transfer of H Shares will be registered. H Share Shareholders whose names appear on the H Shares register of members of the Company on Wednesday, December 9, 2020 are entitled to attend and vote at the EGM. For information relating to attending the EGM for A Share Shareholders, please refer to the A Share announcement of the Company published on the website of the Shenzhen Stock Exchange.

In order to attend the EGM, H Share Shareholders shall lodge all transfer documents together with the relevant share certificates to the Company's H Share registrar, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, not later than 4:30 p.m. on Tuesday, December 8, 2020.

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of the Shareholders at a general meeting must be taken by poll except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Therefore, the resolutions proposed at the EGM will be voted by poll.

7. RECOMMENDATION

The Directors consider that aforementioned resolutions are in the interests of the Company and the Shareholders as a whole. Accordingly, it is recommended that the Shareholders vote in favour of relevant resolutions to be proposed at the EGM.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

NOTICE OF THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9989)

NOTICE OF THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2020 fourth extraordinary general meeting (the “**EGM**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) will be held at 2:30 p.m. on Tuesday, December 15, 2020 at Ballroom, 2/F, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise indicated, capitalized terms used herein shall have the same meanings as defined in the circular of the Company dated November 24, 2020.

ORDINARY RESOLUTION

- 1.00 Proposal on the reappointment of accounting firms.

SPECIAL RESOLUTIONS

- 2.00 Proposal on the application for credit line by the wholly-owned subsidiary to China Guangfa Bank and Industrial Bank and provision of guarantees by the Company;
- 3.00 Proposal on the application for credit by the wholly-owned subsidiary to China Development Bank and provision of guarantees by the Company; and
- 4.00 Proposal on the credit line adjustment of Bank of China and provision of guarantees by the Company.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
November 24, 2020

NOTICE OF THE 2020 FOURTH EXTRAORDINARY GENERAL MEETING

Notes:

1. For the purpose of holding the EGM, the H Share register of members of the Company will be closed from Wednesday, December 9, 2020 to Tuesday, December 15, 2020 (both days inclusive), during which period no transfer of shares can be registered. In order for H Share Shareholders to be qualified to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the H Share registrar of the Company, Tricor Investor Services Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, no later than 4:30 p.m. on Tuesday, December 8, 2020 for registration.

The Shareholders whose names appear on the register of members of the Company on Wednesday, December 9, 2020 are entitled to attend and vote at the EGM.

2. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalves. A proxy need not be a Shareholder.
3. The instrument appointing a proxy must be in writing under the hand of a Shareholder or his attorney duly authorised in writing. If the Shareholder is a legal person, that instrument must be executed either under its seal or under the hand of its director or other attorney duly authorised to sign the same on its behalf.
4. In order to be valid, the proxy form must be deposited, for H Share Shareholders, to the H Share registrar of the Company, Tricor Investor Services Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong not less than 24 hours before the time for holding the EGM. If the proxy form is signed by a person under a power of attorney or other authority, a notarized copy of that power of attorney or other authority shall be deposited at the same time as mentioned in the proxy form. Completion and return of the proxy form will not preclude the Shareholders from attending and voting in person at the EGM or any adjourned meetings should they so wish.
5. Shareholders shall produce their identification documents and supporting documents in respect of the shares of the Company held when attending the EGM. If corporate Shareholders appoint authorised representative to attend the EGM, the authorised representative shall produce his/her identification documents and a notarized copy of the relevant authorisation instrument signed by the board of directors or other authorised parties of the corporate Shareholders or other notarized documents allowed by the Company. Proxies shall produce their identification documents and the proxy form signed by the Shareholders or their attorney when attending the EGM.
6. The EGM is expected to take for less than half a day. Shareholders attending the EGM shall be responsible for their own travel and accommodation expenses.
7. All voting at the EGM will be conducted by poll.